ChromaDex (CDXC) Reports In-Line Q2 EPS

ChromaDex (NASDAQ: CDXC) reported Q2 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $17.7 million versus the consensus estimate of $17.16 million. Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was a profit of $0.6 million, a $0.1 million improvement from the prior year quarter.

For earnings history and earnings-related data on ChromaDex (CDXC) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Inhibrx Biosciences (INBX) Reiterated at Market Perform by Citizens on INBRX-106 Ph2 Results
• Halozyme prices $1.3B convertible notes offering due 2033